Lakefront Biotherapeutics NV vs Madrigal Pharmaceuticals
Lakefront Biotherapeutics NV is the larger business, with $1.26bn of revenue in fiscal 2025 against $958m for Madrigal Pharmaceuticals (1.3 times as much). Madrigal Pharmaceuticals grew faster (432.1% against 321.6%). Lakefront Biotherapeutics NV kept more of each dollar of sales as profit: a net margin of 28.9% against -30.1%. Lakefront Biotherapeutics NV carries less debt relative to equity (0.0% against 80.6%).
| Latest fiscal year | Lakefront Biotherapeutics NVLKFT, 2025 | Madrigal PharmaceuticalsMDGL, 2025 |
|---|---|---|
| Revenue | $1.26bn | $958m |
| Revenue growth | 321.6% | 432.1% |
| Net income | $363m | −$288m |
| Operating margin | 26.5% | -31.3% |
| Net margin | 28.9% | -30.1% |
| Return on equity | 10.7% | -42.5% |
| Free cash flow | −$307m | −$190m |
| Cash | $103m | $199m |
| Total debt | $0 | $486m |
| Debt to equity | 0.0% | 80.6% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 915 |
| Market value | $2.11bn | $9.38bn |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 202 sales |